BridgeBio Oncology Therapeutics (BBOT) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BridgeBio Oncology Therapeutics (BBOT) has outperformed Veraxa Biotech (VRXA) over the past year, losing 85.4% versus a loss of 90.1%. Veraxa Biotech is the larger company by market cap ($147.1 million vs $145.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | VRXA |
|---|---|---|
| Share price | $1.81 | $1.04 |
| Market cap | $145.25M | $147.06M |
| 1-day change | -2.69% | +0.97% |
| YTD return | -85.54% | -90.25% |
| 1-year return | -85.39% | -90.10% |
| P/E ratio (TTM) | 3.42 | — |
| EPS (TTM) | $0.53 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-134.04M | — |
| 52-week high | $14.87 | $27.36 |
| 52-week low | $1.79 | $0.90 |
| Distance from 52-week high | -87.83% | -96.20% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1060.22% | — |
| Average volume | 631.56K | 267.82K |
| Shares outstanding | 80.25M | 141.41M |
| Employees | 92 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Veraxa Biotech
VRXA stock →Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
BBOT vs VRXA FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $147.06M compared with $145.25M for BridgeBio Oncology Therapeutics (BBOT).
Which stock has performed better over the past year, BBOT or VRXA?
BBOT returned -85.39% over the past 12 months, compared with -90.10% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.